We determinedthe reference interval for the carboxyterminal propeptide of type I procollagen (PICP), an indicator of the synthesis of type I collagen, in cerebrospinal fluid (CSF) by studying 32 infants and children, ages 15 years. The concentration of PICP is age dependent, with particularly high concentrations occurring in children younger than 1.5 years. In older children the concentration is stable (reference interval 20-92 gfL). We also investigated the possibilitythat PICP in CSF could reflect local fibroproliferative changes in the arachnoid in a cohort of 42 children with acute lymphoblastic leukemia who were monitored by repeated sampling in connection with intrathecal therapy. Initially, there was no difference in PICP between the children with newly diagnosed leukemia and the controls. PICP concentrations were significantly higher (P <0.01) during intrathecal methotrexate therapy, with median values above the reference interval. Continuous corticosteroid treatment was associated with a significant decrease in PICP (P <0.02 and P <0.01, respectively, in two groups treated according to different protocols), close to the lower limit of the reference interval. Intrathecally administered methotrexate and systemic corticosteroid treatment are known to be associated with the development of arachnoiditisand with general repression of collagen synthesis, respectively. We conclude that PICP in CSF is a sensitive indicator of local fibroproliferation and ongoing collagen synthesis. We undertook the present work to find out whether the assay of PICP can be used in studies of CSF and whether a process leading to arachnoiditis also stimulates the rate of collagen synthesis in the meninges. We first established the reference interval of PICP in CSF in children without any structural lesion of the central nervous system (CNS), and subsequently investigated children with recently diagnosed ALL who were receiving repeated intrathecal injections of methotrexate. We hypothesized that if this drug does induce a fibroproliferative response in the meninges, this treatment should lead to an increase in the PICP concentration that would be measurable in the CSF.
reference interval arachnolditis fibroproliferation chemotherapy methotrexate te,(jgds Type I collagen, the most abundant collagenous protern in most connective tissues (1) , is synthesized in a larger precursor form, type I procollagen, from which the additional sequences are removed by cleavage by two specific proteolytic enzymes (2) . At least one of these extensions, the carboxyterminal propeptide of type I procollagen (PICP), can be found in the free form in blood and interstitial fluid (3), where its concentration is considered to reflect therateoftypeI collagen synthesis We developed a radioimmunoassay recently for assessing the concentration of PICP in serum (5) . Inflammation in any location is known to trigger a fibroproliferative reaction in the tissue involved (6) .
Such a reaction involves the proliferation of fibroblastic cells and enhanced expression of extracellular matrix components, including fibronectin and collagen oftypes I and ifi(7). These phenomena have also been described as taking place in the pia-arachnoid membranes and between thenerverootsincasesofadhesive arachnoiditis induced by radiographic contrast material
(8).
There is also a report of a child with leukemia in whom scarring of the subarachnoid space led to an inability to walk (9 (14) .
We undertook the present work to find out whether the assay of PICP can be used in studies of CSF and whether a process leading to arachnoiditis also stimulates the rate of collagen synthesis in the meninges. We first established the reference interval of PICP in CSF in children without any structural lesion of the central nervous system (CNS), and subsequently investigated children with recently diagnosed ALL who were receiving repeated intrathecal injections of methotrexate. We hypothesized that if this drug does induce a fibroproliferative response in the meninges, this treatment should lead to an increase in the PICP concentration that would be measurable in the CSF. In the third, re-induction phase, the standardrisk patients received prednisolone daily for one week, and a single dose of vincristine; this regimen was repeated at eight-week intervals.
MaterIals and Methods

Subjects
Between these intervals, single doses of methotrexate were administered as above, also at eight-week intervals.
Maintenance ther- The main characteristics of the assay are comparable with those of a method for PICP reported elsewhere (17) . The molecular size of the PICP antigen was studied by gel filtration as described previously (5) .
StatisticalAnalyses
We tested the distributions of the variables statistically for normality. 
Resufts
The distribution of PICP concentrations in the CSF of the control children is shown in Figure 1 . QUite high concentrations are seen at ages <1. 5 The children with ALL from whom a sample representing the time of diagnosis was available were all ages >1.5 years (Figure 1) , and their initial PICP concentrations did not differ significantly from those of the control children (P = 0.059, Student's t-test), although fiveof 22 CSF samples exceeded the reference interval.
The changes in PICP values in CSF during chemotherapy for ALL are shown in Figure 2 . PICP concentrations were significantly higher during the second phase, methotrexate therapy, than at the time of diagnosis (P <0.01, Wilcoxon signed-rank test), a phenomenon observable during both treatment protocols. Most of the PICP values were well above the upper limit of the reference interval during this phase (Figure 2) .
The effect of continuous corticosteroid treatment on PICP in CSF was monitored during the first (induction) phase in the standard-risk patients (Figure 2A) and later, during the third (re-induction) phase, in the intermediate-and high-risk patients ( Figure 2B ). Both of these treatment phases were associated with significant decreases in the CSF concentration of PICP (P <0.02 and <0.01, respectively;
Wilcoxon signed-rank test). A similar decrease was seen in the intermediate-and high-risk patients during the first week of the induction therapy. The lowest median values obtained during these phases were close to the lower limit of the reference interval, indicating a marked repression of type I collagen synthesis. One-week pulses of corticosteroid treatment were given to the standard-risk patients at eight-week intervals during the third therapy phase, with intrathecal and systemic methotrexate in between, also at eight-week intervals. The PICP values observed here were similar to those observed during the second, The correlation between the PICP in CSF and protein during the second, methotrexate therapy, phase was P <0.02 (r8 = 0.42).The increase in PICP was generally greater than the increase in total protein (Table 2) .
Our material included CSF samples from five patients at the time that CNS leukemia relapse was diagnosed. Their PICP values ranged from 143 to 630 g/L. One of these children was in the phase of intravenous and intrathecal methotrexate therapy, whereas intrathecal therapy was no longer included in the treatment of the others or all leukemia therapy had already been stopped. the highest values (18,19) . There is evidence that most of the PICP in blood is normally derived from metabolism in the bones, where type I collagen constitutes >90% of the organic matrix.
PICP is a globular protein with a molecular mass of -'100 000 Da, which cannot be expected to cross the blood-brain barrier. Thus its presence in the CSF is most probably derived from local collagen synthesis. The age dependency resembles that of PICP in blood, most probably reflecting the growth rate of surrounding collagen-rich tissues such as the meninges.
Most drugs for the systemic treatment of ALL do not penetrate the blood-brain barrier (20 was always associated with a low absolute (Figure 2 ) and relative (Table 2) Some have suggested that corticosteroids lessen the severity of arachnoiditis (24, 25) , and our observations agree with this. It is worth considering administering these drugs simultaneously with the intrathecal injections during phases of methotrexate therapy.
The results indicate that the concentration of PICP in the CSF acts as a sensitive marker of local collagen synthesis and fibroproliferation, processes that can be started and stopped by methotrexate and corticosteroids, respectively. PICP is nonspecific with respect to the cause of the process, as evidenced by the fact that CNS leukemia may also increase the concentration of PICP in the CSF. Price 
